123 related articles for article (PubMed ID: 8937792)
1. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction.
Oishi M; Mochizuki Y; Hara M; Yoshihashi H; Takasu T
Clin Neuropharmacol; 1996 Dec; 19(6):526-31. PubMed ID: 8937792
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction].
Sakamoto T; Harimoto K; Inoue S; Konishi A
No To Shinkei; 1996 Sep; 48(9):805-9. PubMed ID: 8888028
[TBL] [Abstract][Full Text] [Related]
3. Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis.
Wada T; Yasunaga H; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2828-2837. PubMed ID: 27567296
[TBL] [Abstract][Full Text] [Related]
4. Single lacunar brain infarction with transient signs versus those with long-lasting signs.
Oishi M; Mochizuki Y; Shikata E
Int Angiol; 1999 Sep; 18(3):206-9. PubMed ID: 10688419
[TBL] [Abstract][Full Text] [Related]
5. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I
J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166
[TBL] [Abstract][Full Text] [Related]
6. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
Imamura T; Kiguchi S; Kobayashi K; Ichikawa K; Yamazaki Y; Kojima M
Arzneimittelforschung; 2003; 53(10):688-94. PubMed ID: 14650360
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery].
Itoh H; Yamatani K; Oshida N; Shioi M; Takaba M; Kamiyama H; Itoh M
No To Shinkei; 1998 Feb; 50(2):147-55. PubMed ID: 9513204
[TBL] [Abstract][Full Text] [Related]
8. The effect of ozagrel sodium on photochemical thrombosis in rat: therapeutic window and combined therapy with heparin sodium.
Arii K; Igarashi H; Arii T; Katayama Y
Life Sci; 2002 Nov; 71(25):2983-94. PubMed ID: 12384182
[TBL] [Abstract][Full Text] [Related]
9. Blood flow differences between leuko-araiosis with and without lacunar infarction.
Oishi M; Mochizuki Y; Takasu T
Can J Neurol Sci; 1998 Feb; 25(1):70-5. PubMed ID: 9532285
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
[TBL] [Abstract][Full Text] [Related]
11. [The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction].
Takabatake Y; Uno E; Wakamatsu K; Yamazaki N; Hashimoto N; Tsuchiya Y
No To Shinkei; 2003 Jul; 55(7):589-93. PubMed ID: 12910992
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibrinopeptide A, beta-thromboglobulin, and platelet factor 4 in diabetic retinopathy.
Roy MS; Podgor MJ; Rick ME
Invest Ophthalmol Vis Sci; 1988 Jun; 29(6):856-60. PubMed ID: 2967258
[TBL] [Abstract][Full Text] [Related]
13. Acetazolamide reactivity in atherothrombotic, cardioembolic and lacunar infarctions.
Oishi M; Mochizuki Y; Shikata E; Mizutani T
Keio J Med; 2000 Feb; 49 Suppl 1():A117-9. PubMed ID: 10750358
[TBL] [Abstract][Full Text] [Related]
14. [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness].
Nishi K; Mizuguchi M; Tachibana H; Watanabe K; Ooka T; Fujimura M; Matsuda T
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Sep; 35(9):927-33. PubMed ID: 9396248
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of fibrinopeptide A in survivors of cerebral infarction.
Landi G; Barbarotto R; Morabito A; D'Angelo A; Mannuccio Mannucci P
Stroke; 1990 Mar; 21(3):424-7. PubMed ID: 2137945
[TBL] [Abstract][Full Text] [Related]
16. [Sodium ozagrel].
Kitagawa Y
Nihon Rinsho; 2006 Oct; 64 Suppl 7():554-61. PubMed ID: 17461205
[No Abstract] [Full Text] [Related]
17. Cerebrovascular acetazolamide reactivity and platelet function in asymptomatic cerebral thrombosis.
Oishi M; Mochizuki Y
J Neurol Sci; 1999 Jul; 166(2):81-4. PubMed ID: 10475099
[TBL] [Abstract][Full Text] [Related]
18. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction.
Yu Y; Wang L; Zhu X; Liu YF; Ma HY
World J Diabetes; 2021 Dec; 12(12):2096-2106. PubMed ID: 35047123
[TBL] [Abstract][Full Text] [Related]
19. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase].
Nakazawa M; Iizuka K; Ujiie A; Hiraku S; Ohki S
Yakugaku Zasshi; 1994 Dec; 114(12):911-33. PubMed ID: 7869235
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
